Current challenges in the management of follicular lymphoma

Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevi...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of hematologic oncology Vol. 6; no. 1; pp. 13 - 24
Main Authors Yazdy, Maryam Sarraf, Ujjani, Chaitra
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.06.2017
Subjects
antibody-drug conjugate
CAR T cell
follicular lymphoma
ibrutinib
idelalisib
immune checkpoint inhibitor
lenalidomide
minimal residual disease
obinutuzumab
PET-CT
Review
ibrutinib
immune checkpoint inhibitor
CAR T cell
follicular lymphoma
antibody–drug conjugate
PET-CT
minimal residual disease
idelalisib
lenalidomide
obinutuzumab
Online AccessGet full text

Cover

More Information
Summary:Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevitably relapse. The inability to achieve a complete remission and an early progression of disease have recently been determined to be indicative of poorer long-term outcomes. A greater understanding of the pathogenesis of follicular lymphoma has enabled the development of targeted therapies, which may improve standard treatment approaches. Examples include lenalidomide and obinutuzumab, which are currently in front-line Phase III investigation. Other therapies of interest include small molecule inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2045-1393
2045-1407
DOI:10.2217/ijh-2017-0003